• 1
    Portlock CS, Rosenberg SA. No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 1979; 90: 1013.
  • 2
    Ezdinli EZ, Costello WG, Silverstein MW et al. Moderate versus intensive chemotherapy of prognostically favorable non-Hodgkin's lymphoma: A progress report. Cancer 1980; 46: 2933.
  • 3
    The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 21122135.
  • 4
    Kennedy BJ, Bloomfield CD, Kiang DT et al. Combination versus single agent chemotherapy in lymphocytic lymphoma. Cancer 1978; 41: 2329.
  • 5
    Ezdinli EZ, Anderson JR, Melvin F et al. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 1985; 3: 769775.
  • 6
    Rosenberg SA. Is intensive treatment of favorable non-Hodgkin's lymphoma necessary? In: WiernikP, ed. Controversies in Oncology. New York: John Wiley & Sons, 1982; 4560.
  • 7
    Rosenberg SA. The low-grade non-Hodgkin's lymphomas: Challenges and opportunities: Karnofsky Memorial Lecture. J Clin Oncol 1985; 3: 299310.
  • 8
    Hoogstraten B, Owens AJ, Lenhard RE et al. Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma. Blood 1969; 33: 370378.
  • 9
    Luce JK, Gamble JF, Wilson HE et al. Combined cyclophosphamide, vincristine, and prednisolone therapy of malignant lymphoma. Cancer 1971; 28: 306317.
  • 10
    Carbone PP, Spurr C. Management of patients with malignant lymphoma-A comparative study with cyclophosphamide and vinca alkaloids. Cancer Res 1968; 28: 811822.
  • 11
    Landberg TG, Hakansson LG, Moller TR et al. CVP-remission maintenance in stage I and II non-Hodgkin's lymphomas. Cancer 1979; 44: 831838.
  • 12
    Kaplan EL, Meier P. Non-parametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457481.
  • 13
    Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1977; 35: 139.
  • 14
    Cox DR. Regression model and life table. J R Stat Soc 1972; 34: 187220.
  • 15
    Cadman E, Drislane F, Waldron JA Jr et al. High-dose pulse chlorambucil: Effective therapy for rapid remission induction in nodular lymphocytic poorly differentiated lymphoma. Cancer 1982; 50: 10371041.
  • 16
    Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 14711475.
  • 17
    Acker B, Hoppe RT, Colby TV et al. Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1983; 1: 1116.
  • 18
    Jones R, Young RC, Berard CW et al. Histologic progression in non-Hodgkin's lymphoma: Implications for survival and clinical trials (Abstr). Proc Am Soc Clin Oncol 1979; 20: 353.
  • 19
    Erickson DJ, Cousar JB, Flexner JM et al. Transformation of follicular center cell lymphomas (Lukes-Collins classification): Progression of small cleaved cell type to transformed cell type (Abstr). Lab Invest 1981; 44: 16a.
  • 20
    Greene MH, Young RC, Merrill HM et al. Evidence of a treatment dose-response in acute non-lymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 1983; 43: 18911898.
  • 21
    Dumont J, Thiery JP, Mazabrand A et al. Acute myeloid leukemia following non-Hodgkin's lymphoma: Danger of prolonged use of chlorambucil as maintenance therapy. Nouv Rev Fr Hematol 1980; 22: 391404.